SPR001-205 A Phase 2 Study to Evaluate the Safety, Pharmacokinetics, and Exploratory Pharmacodynamics of SPR001 (Tildacerfont) in Children Aged 6 to 17 Years with Congenital Adrenal Hyperplasia

Project: Research project

Project Details

Description

SPR001-205 A Phase 2 Study to Evaluate the Safety, Pharmacokinetics, and Exploratory Pharmacodynamics of SPR001 (Tildacerfont) in Children Aged 6 to 17 Years with Congenital Adrenal Hyperplasia
StatusActive
Effective start/end date7/12/219/30/26

Funding

  • SPRUCE BIOSCIENCES, INC.

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.